{"nctId":"NCT00805675","briefTitle":"Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB","startDateStruct":{"date":"2008-11"},"conditions":["Hepatitis B Virus"],"count":83,"armGroups":[{"label":"Telbivudine 600 mg monotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Telbivudine"]},{"label":"Tenofovir disproxil fumarate 300 mg monotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tenofovir"]},{"label":"Telbivudine 600 mg and Tenofovir 300 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Telbivudine plus tenofovir"]}],"interventions":[{"name":"Telbivudine","otherNames":[]},{"name":"Tenofovir","otherNames":[]},{"name":"Telbivudine plus tenofovir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic HBV infection, defined as positive serum HBsAg for at least 6 months, or HBsAg positive \\> 3 months and negative for IgM anti-HBc and positive for IgG anti-HBc\n* Age \\< 40 years old\n* HBeAg positive\n* HBV DNA \\> or = to 10\\^7 copies/mL by Abbott real-time PCR\n* ALT \\< or = to 1 ULN\n* Willing and able to provide written informed consent\n* No prior oral HBV therapy (e.g., nucleotide and/or nucleoside therapy or other investigational agents for HBV infection)\n* Is willing and able to comply with the study drug regimen and all other study procedures and requirements\n* Is willing and able to provide written informed consent before any study assessment is perform\n\nExclusion Criteria:\n\n* Decompensated liver disease defined as direct (conjugated) bilirubin \\> 1.2 × ULN, PT \\> 1.2 × ULN, platelets \\< 150,000/mm3, serum albumin \\< 3.5 g/dL, or prior history of clinical hepatic decompensation (e.g. ascites, jaundice, encephalopathy, variceal hemorrhage).\n* Received interferon (pegylated or not) therapy within 6 months of the screening visit\n* α-fetoprotein \\> 50 ng/mL\n* Evidence of hepatocellular carcinoma (HCC)\n* Co-infection with HCV (by serology), or HIV,\n* Significant renal, cardiovascular, pulmonary, or neurological disease.\n* Received solid organ or bone marrow transplantation.\n* Is currently receiving therapy with immunomodulators (e.g., corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion.\n* Has proximal tubulopathy.\n* Use of other investigational drugs at the time of enrollment, or within 30 days\n* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes\n* Is pregnant or breastfeeding.\n* Is a women of child-bearing potential (WOCBP)unless post-menopausal or using one or more acceptable method of contraception.\n* Patient has any other concurrent medical or social condition likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study.\n* Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.\n* Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir.\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12.","description":"Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. Serum HBV DNA determinations were performed at a central laboratory through use of the COBAS TaqMan™ HBV DNA assay (Roche Molecular Systems, Pleasanton, CA, USA) which utilized the Real-time polymerase chain reaction (PCR) method and automated extraction by Cobas Ampliprep (threshold for detection 12 IU/mL). The Screening serum HBV DNA values must be ≥ 7 log10 copies/mL by COBAS TaqMan™ HBV DNA assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.852","spread":"0.9330"},{"groupId":"OG001","value":"-4.175","spread":"0.7476"},{"groupId":"OG002","value":"-4.374","spread":"0.9774"}]}]}]},{"type":"SECONDARY","title":"Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Weeks 2, 4 and 8.","description":"Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA. Serum HBV DNA determinations were performed at a central laboratory through use of the COBAS TaqMan™ HBV DNA assay (Roche Molecular Systems, Pleasanton, CA, USA) which utilized the Real-time polymerase chain reaction (PCR) method and automated extraction by Cobas Ampliprep (threshold for detection 12 IU/mL). The Screening serum HBV DNA values must be ≥ 7 log10 copies/mL by COBAS TaqMan™ HBV DNA assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.657","spread":"0.6683"},{"groupId":"OG001","value":"-2.541","spread":"0.4876"},{"groupId":"OG002","value":"-2.689","spread":"0.5951"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.985","spread":"0.8019"},{"groupId":"OG001","value":"-3.060","spread":"0.6230"},{"groupId":"OG002","value":"-3.225","spread":"0.8149"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.474","spread":"0.8829"},{"groupId":"OG001","value":"-3.621","spread":"0.6737"},{"groupId":"OG002","value":"-3.845","spread":"0.849"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Are Polymerase Chain Reaction(PCR)Negative at Week 12","description":"Polymerase Chain Reaction (PCR) Negative is defined as HBV DNA levels \\<25 copies/ml.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieve Hepatitis B \"e\" Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 12","description":"HBeAg loss is defined as the loss of detectable serum HBeAg in a patient who was HBeAg positive at baseline. HBeAg seroconversion is defined as HBeAg loss with detectable Hepatitis B 'e' antibody (HBeAb). HBeAg stands for hepatitis B \"e\" antigen. This antigen is a protein from the hepatitis B virus that circulates in infected blood when the virus is actively replicating. The presence of HBeAg suggests that the person is infectious and is able to spread the virus to other people.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Characterization of Very Early Viral Kinetics Through Estimated Viral Load","description":"The underlying bi-phasic model of viral kinetics can be described as follows:\n\nV(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise all infected and uninfected target cells, and δ the rate of infected cell loss","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"0.6"},{"groupId":"OG001","value":"8.7","spread":"0.8"},{"groupId":"OG002","value":"8.7","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Characterization of Very Early Viral Kinetics Through Viral Clearance","description":"The underlying bi-phasic model of viral kinetics can be described as follows:\n\nV(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise all infected and uninfected target cells, and δ the rate of infected cell loss","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"0.19"},{"groupId":"OG001","value":"1.19","spread":"0.62"},{"groupId":"OG002","value":"1.08","spread":"0.75"}]}]}]},{"type":"SECONDARY","title":"Characterization of Very Early Viral Kinetics Through Rate of Infected Cell Loss","description":"The underlying bi-phasic model of viral kinetics can be described as follows:\n\nV(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise all infected and uninfected target cells, and δ the rate of infected cell loss","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.01"},{"groupId":"OG001","value":"0.06","spread":"0.02"},{"groupId":"OG002","value":"0.05","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Characterization of Very Early Viral Kinetics Through Efficiency Factor of Blocking Virus Production.","description":"The underlying bi-phasic model of viral kinetics can be described as follows:\n\nV(t) (1 )pI(t) cV(t) I(t) (1 ) (T I(t))V(t) I(t) where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise allinfected and uninfected target cells, and δ the rate of infected cell loss","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":"1.9"},{"groupId":"OG001","value":"99.0","spread":"1.3"},{"groupId":"OG002","value":"99.1","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Characterization of Very Early Viral Kinetics Through Half-live of Free Virus","description":"The underlying bi-phasic model of viral kinetics can be described as follows:\n\nV(t) (1 )pI(t) cV(t)I(t) (1 ) (T I(t))V(t) I(t)where V denotes serum viral load, I productively infected cells, ε the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, η the efficiency factor of blocking de novo infection, β the de novo infection rate, Tg comprise all infected and uninfected target cells, and δ the rate of infected cell loss","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":"4.4"},{"groupId":"OG001","value":"16.4","spread":"5.8"},{"groupId":"OG002","value":"18.9","spread":"6.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Influenza","Influenza like illness","Abdominal Pain Upper","Oropharyngeal pain","Dizziness"]}}}